Aelix completes €11.5 M Series A funding for therapeutic HIV vaccine
11 January 2016 | By Victoria White
The proceeds will support the development of Aelix’s lead candidate HTI immunogen as a therapeutic vaccine against HIV infection up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individuals...